Access the comprehensive database of immunotherapy company domains. From checkpoint inhibitor pioneers to bispecific antibody developers, discover verified websites of companies harnessing the immune system to fight cancer and disease.
Navigate the immuno-oncology landscape with comprehensive data on immunotherapy developers and innovators.
Immunotherapy has revolutionized cancer treatment, with checkpoint inhibitors and cellular therapies achieving remarkable clinical outcomes. Our database provides access to PD-1/PD-L1 developers, bispecific antibody companies, tumor-infiltrating lymphocyte specialists, and innate immunity modulators.
Whether you're tracking combination therapy trials, analyzing competitive landscapes in specific tumor types, or identifying licensing opportunities, our database delivers intelligence on companies advancing next-generation immunotherapies.
"The global immunotherapy market is projected to exceed $180 billion by 2028, with combination approaches and novel targets driving next-generation therapies." Our CAR-T Therapy list offers complementary insights.
-- Immuno-Oncology Market Analysis, 2024Comprehensive coverage of the immuno-oncology sector. Expand your research by viewing the Biologics Developers section.
PD-1, PD-L1, CTLA-4
T-cell engagers. Professionals often consult our Drug Discovery Companies data.
Tumor-infiltrating lymphocytes
NK cells, macrophages. Discover more in the Cell Therapy Developers category.
Therapeutic immunization
Viral immunotherapy
Get instant access to 3,200+ immunotherapy company domains with comprehensive enrichment data. You may also be interested in our Clinical Stage Biotech dataset.
View Pricing Plans Back to Biotech & Biomedical